Exagen Inc is a molecular diagnostics company that specializes in the development and commercialization of innovative tests for autoimmune diseases. The company was founded in 2002 and is based in Albuquerque, New Mexico, USA. Exagen's mission is to improve the lives of patients suffering from autoimmune diseases through early and accurate diagnosis, helping physicians make informed treatment decisions.
Exagen's core product is AVISE® CTD, a comprehensive test designed to aid in the diagnosis and management of systemic lupus erythematosus (SLE) and other connective tissue diseases (CTD). This test uses advanced technology to detect specific biomarkers associated with autoimmune conditions, providing physicians with valuable insights into a patient's disease activity and potential risks.
In addition to AVISE® CTD, Exagen offers other diagnostic tests like AVISE® Vasculitis, AVISE® MTX, and AVISE® SLE Prognostic. These tests provide valuable information to physicians, helping them personalize treatment plans for patients with autoimmune diseases and monitor their progress over time.
The company's commitment to innovation and research has led to the development of cutting-edge diagnostic solutions that have the potential to improve patient outcomes and contribute to advancements in the field of autoimmune disease management. Through its products and services, Exagen aims to address the unmet needs of patients and healthcare providers in the field of autoimmune diagnostics, ultimately enhancing the quality of patient care and disease management.